Merck Research Laboratories, Kenilworth, NJ. Background: We present a post hoc analysis from 3 phase III clinical trials examining the effects of mometasone furoate/formoterol (MF/F) combination therapy on asthma deterioration in subjects previously not well controlled on low-, medium-, or high-dose inhaled corticosteroids (ICS). Methods: A 2-to 3-week run-in period with twice-daily (BID) MF 100 mg (MF/F 100/10 mg BID study), MF 200 mg (MF/F 200/10 mg BID study), or MF 400 mg (MF/F 400/10 mg BID study) was performed before subjects (aged $12 years) were randomized to BID: MF/F 100/10 mg, MF 100 mg, F 10 mg, or placebo for 26 weeks (n ¼ 746; MF/F 100/10 mg BID study); MF/F 200/10 mg, MF 200 mg, F 10 mg, or placebo for 26 weeks (n ¼ 781; MF/F 200/10 mg BID study); or MF/F 200/10 mg, MF/F 400/10 mg, or MF 400 mg for 12 weeks (n ¼ 728; MF/F 400/10 mg BID study). Assessment of asthma deterioration (ie, 20% decrease in forced expiratory volume in 1 s [FEV 1 ], 30% decrease in peak expiratory flow [PEF] on $2 consecutive days, or clinically judged deterioration [ie, emergency treatment, hospitalization, or treatment with excluded medications]) was a coprimary endpoint for the MF/ F 100/10 mg BID and 200/10 mg BID studies and a secondary endpoint for the MF/F 400/10 mg BID study. Post hoc pair-wise comparisons of pooled MF/F vs pooled MF, F, and placebo treatment groups were performed. Results: Sample sizes in this pooled analysis were 861 for MF/F, 620 for MF, 390 for F, and 384 for placebo. There was a significantly lower incidence of asthma deterioration with MF/F (17.2%) versus MF (26.1%; P ¼ 0.002), F (49.5%; P , 0.001), and placebo (50.8%; P , 0.001). Incidence of individual asthma deterioration criteria was 7.0% for MF/F, 10.0% for MF, 13.8% for F, and 17.7% for placebo for FEV 1 reduction; 7.5%, 12.6%, 27.2%, and 26.3%, respectively, for PEF reduction; and 2.1%, 2.6%, 6.7%, and 5.2% for clinically judged deterioration. Conclusions: MF/F-treated subjects experienced a significantly lower rate of asthma deterioration compared with MF, F, and placebo in subjects previously not well controlled on low-, medium-, or high-dose ICS. Background: Mometasone furoate/formoterol (MF/F) combination therapy is a new treatment recently approved by the US Food and Drug Administration for the treatment of persistent asthma and currently under regulatory review by Canadian authorities. We report findings from a noninferiority study that compared effects of MF/F and fluticasone propionate/salmeterol (FP/S) combination therapies on pulmonary function and onset of action in subjects with persistent asthma. Methods: This randomized, active-controlled, multicenter, noninferiority trial enrolled subjects (aged $12 years) previously treated with medium-dose inhaled corticosteroid alone or combined with a long-acting b 2 -agonist. Following a 2-to 4-week run-in treatment period with MF administered via a metered-dose inhaler (MDI) 200 mg twice daily (BID), eligible subjects were randomized to MF/F-MDI 200/10 mg BID or FP/S administered via a dry powder inhaler (DPI) 250/50 mg BID for 12 weeks. The primary endpoint of this trial was change from baseline in area under the curve (AUC) in forced expiratory volume in 1 second (FEV 1 ) measured serially for 0 to 12 hours postdose (FEV 1 AUC 0212h ). Key secondary endpoints included onset of action, defined as change from baseline in FEV 1 at 5 minutes postdose on day 1. Results: 722 subjects were randomized to MF/F-MDI (n ¼ 371) or FP/S-DPI (n ¼ 351). The trial's primary endpoint was met, demonstrating that MF/F administered via an MDI was noninferior to FP/S administered via a DPI in the patient population investigated. Mean FEV 1 AUC 0212h at endpoint for MF/F-MDI and FP/S-DPI was 3.43 versus 3.24 L · h, respectively (95%, CI, 20.40 to 0.76). Analysis of onset-of-action characteristics revealed that MF/ F's effect on lung function occurred significantly faster than the effect observed with FP/S-DPI. MF/F-MDI was associated with a 200-mL mean increase from baseline in FEV 1 at 5 minutes postdose (first scheduled measurement) on the first day of treatment vs a 90-mL increase for FP/S-DPI (P , 0.001).
Conclusions: This trial demonstrated that MF/F 200/10 mg BID administered via an MDI was noninferior to FP/S 250/50 mg BID administered via a DPI in its effect to improve lung function as measured by FEV1 AUC0-12h. However, the onset of action for this effect was significantly faster with MF/F-MDI than with FP/S-DPI. Background: Multiple strengths of mometasone furoate/formoterol (MF/F) metered-dose inhaler combination therapy have been investigated as new treatments for asthma. We report efficacy/safety findings from an MF/F study in subjects with severe asthma previously uncontrolled on high-dose inhaled corticosteroids (ICS) with or without a long-acting ß 2 -agonist (LABA). Methods: This was a 3-month, randomized, double-blind, parallel-group, multicenter study with a 2-to 3-week open-label run-in period during which subjects received mometasone furoate (MF) 400 mg twice daily (BID). Subjects ($12 years) were randomized to MF/F 200/10 mg BID, MF/F 400/10 mg BID, or MF 400 mg BID. The primary endpoint was the area under the curve (AUC) of the change in serial (0212 hours) forced expiratory volume in 1 second (FEV 1 ) for MF/F 400/10 mg vs MF 400 mg from baseline to week 12. Adverse events (AEs) and other clinical safety measures were recorded. Results: 728 subjects were randomized (mean: age, 47.9 years; asthma duration, 14.0 years; FEV 1 % predicted, 66.3; reversibility, 22.9%; Asthma Control Questionnaire score, 1.93). Improvements in mean changes from baseline in 
